Mechanisms and controversies in mutant Cul3-mediated familial hyperkalemic hypertension

Mohammed Z Ferdaus1, James A McCormick1

  • 1Division of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University , Portland, Oregon.

Insights

Autosomal dominant mutations in Cullin-3 (CUL3) cause familial hyperkalemic hypertension (FHHt). This review explores how CUL3-∆9 mutations disrupt WNK kinase degradation, impacting kidney function and blood pressure regulation.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Genetics

Background:

  • Autosomal dominant mutations in Cullin-3 (CUL3) are linked to severe familial hyperkalemic hypertension (FHHt).
  • CUL3 mutations lead to exon 9 skipping, producing a CUL3-∆9 protein with a 57-amino acid deletion.
  • The exact mechanism of CUL3-∆9 in causing FHHt remains debated, with conflicting in vitro and in vivo data.

Purpose of the Study:

  • To review current knowledge on CUL3-∆9's molecular actions in FHHt.
  • To analyze findings from both in vitro studies and in vivo models, including a recently developed mouse model.
  • To discuss the implications of these findings for understanding FHHt pathogenesis.

Main Methods:

  • Review of existing literature on CUL3 mutations and FHHt.
  • Analysis of in vitro data regarding CUL3-∆9 protein function and ubiquitination pathways.
  • Evaluation of in vivo data from a CUL3-∆9 mouse model and direct experimental testing of proposed mechanisms.

Main Results:

  • CUL3-∆9 disrupts the normal degradation of with-no-lysine [K] kinases (WNKs) via the proteasome.
  • This leads to overactivation of WNK targets, affecting the thiazide-sensitive Na+–Cl– cotransporter and potentially causing oxidative stress.
  • Direct testing of the haploinsufficiency model in vivo suggests dominant effects of CUL3-∆9 contribute to FHHt, beyond simple degradation.

Conclusions:

  • The pathogenesis of CUL3-∆9-mediated FHHt involves complex molecular mechanisms.
  • Both impaired WNK degradation and potential dominant effects of the mutant CUL3 protein contribute to the disease.
  • Further research integrating in vitro and in vivo findings is crucial to fully elucidate FHHt development.

Related Concept Videos

Protein Families02:47

Protein Families

Protein families are groups of homologous proteins; that is, they have similarities in amino acid sequences and three-dimensional structures. Protein families usually occur because of gene duplication, where an additional copy of a gene is inserted into the genome of an organism.   Mutations that change the amino acids but still allow the protein to be properly synthesized, will lead to new protein family members.   If these new proteins contain similar amino acids in key...
17.2K
Protein Families02:47

Protein Families

4.5K
Gene Families01:57

Gene Families

Gene families consist of groups of genes proposed to have originated from a common ancestor. Typically these arise through events in which a gene or genes are mistakenly duplicated during cell division. Unlike their parent genes (which are subject to selection pressure to maintain function), these gene copies do not need to preserve their sequences and may evolve at a relatively faster rate.
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
10.0K
Gene Families01:57

Gene Families

3.9K
Family Therapy01:30

Family Therapy

Family therapy conceptualizes psychological challenges as arising from dysfunctional interactions within the family unit, rather than as isolated issues within individuals. This approach seeks to address and transform the patterns of communication, roles, and relationships within families to promote healthier dynamics and emotional well-being for all members.
Strategic Family Therapy
Strategic family therapy emphasizes resolving communication barriers and improving problem-solving abilities...
620
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport01:19

Drug Absorption Mechanism: Carrier-Mediated Membrane Transport

Certain large, lipid-insoluble drug molecules that resemble amino acids, peptides, or glucose, require specialized carrier proteins to facilitate their diffusion across cell membranes. This transport can occur through either facilitated diffusion, which does not require energy input, or active transport, which does require energy input.
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
6.4K